VICCBRE1002-A Phase II Study of the PARP Inhibitor, BSI-201, in Combination with Chemotherapy to Treat Triple Negative Breast Cancer in Brain Metastasis.

Trial Profile

VICCBRE1002-A Phase II Study of the PARP Inhibitor, BSI-201, in Combination with Chemotherapy to Treat Triple Negative Breast Cancer in Brain Metastasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Iniparib (Primary) ; Carboplatin; Gemcitabine
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Jun 2017 Results (n=1368) assessing the association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer including patients from EFC11486 and PrECOG0105 trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 13 Jan 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 12 Dec 2015 Results of pooled analysis from this and other four trials presented at the 38th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top